anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and ticagrelor 90mg twice daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
A single blind RCT was conducted to assess level of state anxiety between two interventional groups; counselling group and video group. 232 consecutive patients were enrolled from the outpatient department who were scheduled to undergo either a gastroscopy or a colonoscopy (diagnostic or therapeutic). The patients were randomly allocated to one of the two intervention groups (A and B) at the time of endoscopy scheduling. All of the patients received regular instructions regarding gut-preparation at the time of appointment and were also provided with written clear instructions. A gastroenterologist provided information about endoscopy, including the exact preparation instructions and information on the importance of bowel preparation and the adverse effects of the agents used.

Depression Anxiety Stress Scale-42 was administered at baseline. Intervention group A (counselling group) was counselled about the procedure, complications and the post-procedure recovery phase and Group B (video group) was also counselled and shown a 5 minutes animated video of the respective procedure in separate room by gastroenterologist. Endoscopies were carried out by trained doctors (endoscopists) with a minimum experience of 1000 endoscopic procedures. Patients in both the groups were interviewed again after the intervention using Depression Anxiety Stress Scale-42.
In the landscape of cancer treatments, the efficacy of coadjuvant molecules remains a focus of attention for clinical research with the aim of reducing toxicity and achieving better outcomes. Most of the pathogenetic processes causing tumour development, neoplastic progression, ageing, and increased toxicity involve inflammation. Inflammatory mechanisms can progress through a variety of molecular patterns. As is well known, the ageing process is determined by pathological pathways very similar and often parallel to those that cause cancer development. Among these complex mechanisms, inflammation is currently much studied and is often referred to in the geriatric field as 'inflammaging'. In this context, treatments active in the management of inflammatory mechanisms could play a role as adjuvants to standard therapies. Among these emerging molecules, Silibinin has demonstrated its anti-inflammatory properties in different neoplastic types, also in combination with chemotherapeutic agents. Moreover, this molecule could represent a breakthrough in the management of age-related processes. Thus, Silibinin could be a valuable adjuvant to reduce drug-related toxicity and increase therapeutic potential. For this reason, the main aim of this review is to collect and analyse data presented in the literature on the use of Silibinin, to better understand the mechanisms of the functioning of this molecule and its possible therapeutic role.
This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
OBJECTIVES: Insight into the aggressiveness of potential breast cancers found in screening may optimize recall decisions. Specific growth rate (SGR), measured on mammograms, may provide valuable prognostic information. This study addresses the association of SGR with prognostic factors and overall survival in patients with invasive carcinoma of no special type (NST) from a screened population.
METHODS: In this historic cohort study, 293 women with NST were identified from all participants in the Nijmegen screening program (2003-2007). Information on clinicopathological factors was retrieved from patient files and follow-up on vital status through municipalities. On consecutive mammograms, tumor volumes were estimated. After comparing five growth functions, SGR was calculated using the best-fitting function. Regression and multivariable survival analyses described associations between SGR and prognostic factors as well as overall survival.
RESULTS: Each one standard deviation increase in SGR was associated with an increase in the Nottingham prognostic index by 0.34 [95% confidence interval (CI): 0.21-0.46]. Each one standard deviation increase in SGR increased the odds of a tumor with an unfavorable subtype (based on histologic grade and hormone receptors; odds ratio 2.14 [95% CI: 1.45-3.15]) and increased the odds of diagnosis as an interval cancer (versus screen-detected; odds ratio 1.57 [95% CI: 1.20-2.06]). After a median of 12.4 years of follow-up, 78 deaths occurred. SGR was not associated with overall survival (hazard ratio 1.12 [95% CI: 0.87-1.43]).
CONCLUSIONS: SGR may indicate prognostically relevant differences in tumor aggressiveness if serial mammograms are available. A potential association with cause-specific survival could not be determined and is of interest for future research.
Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
See Clinical Pharmacology. Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Misoprostol has no clinically significant effect on the kinetics of diclofenac or ibuprofen.

  


Prostaglandins such as misoprostol may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitant use is not recommended.
969,824. Gelatinous vitamin &c. powders. F. HOFFMANN-LA ROCHE & CO. A.G. Sept. 26, 1962 [Sept. 27, 1961], No. 36524/62. Heading A2B. The production of powders involves passing an aqueous colloid solution capable of gelling, at gelling temperature or above, as threads into a liquid in which the colloid is insoluble, cutting up these threads, dispersing the so formed globules in the liquid, gelling them by cooling, and then separating them from the liquid. The colloids are gelatine, pectin, agar, gum tragacanth and sodium alinate. The colloid may carry food colourings and flavourings, feed supplements, vitamins, e.g. vitamins A, D, E and K, carotenoid substances, vitamins B1 and C, and pantothenyl alcohol, plasticizers such as glucose, fructose, sucrose, invert sugar, sorbitol, mannitol and glycerol, antioxidants such as tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, gallic acid esters and 2,2,4-trimethyl-6-ethoxy-1,2-dihydroquinoline, emulsifiers such as lecithin and polyoxyethylene sorbitan monooleate, and diluents or solvents such as sesame, cottonseed, arachis and coconut oils. According to an example, employing the apparatus of the figures, a preparation of vitamin A palmitate, gelatine, sucrose and water is pumped through a pipe 21 into the lower portion 3 of a column 1, there heated to 50‹C., passed through a perforated disc 6 and through 0.25 in. diam. holes in a screen 5 on the disc 6; at the same time, paraffin oil at 5‹C. is pumped through a pipe 15 into the column 1, and, if desired, additional paraffin oil at -5‹C. is pumped into the column 1 at 18; the threads of gelatine preparation from the screen 5 become semiplastic in the cool oil and are cut into globules by a rotating wheel 7 having knife-like spokes; these globules and the oil are stirred in the column 1 by paddles 12 on a rotating shaft 10; the globules gel completely and are removed with the oil at 14, whereupon the globules are filtered from the oil and dried.
PURPOSE: Excess body and visceral fat increase the risk of death from prostate cancer (PCa). This phase II study aimed to test whether weight reduction by > 5% total body weight counteracts obesity-driven PCa biomarkers.
MATERIALS AND METHODS: Forty men scheduled for prostatectomy were randomized into intervention (n = 20) or control (n = 20) arms. Intervention participants followed a weight management program for 4 to 16 weeks before and 6 months after surgery. Control participants received standardized educational materials. All participants attended visits at baseline, 1 week before surgery, and 6 months after surgery. Circulating immune cells, cytokines, and chemokines were evaluated. Weight loss, body composition/distribution, quality of life, and nutrition literacy were assessed. Prostate tissue samples obtained from biopsy and surgery were analyzed.
RESULTS: From baseline to surgery (mean = 5 weeks), the intervention group achieved 5.5% of weight loss (95% CI, 4%-7%). Compared to the control, the intervention also reduced insulin, total cholesterol, LDL cholesterol, leptin, leptin:adiponectin ratio, and visceral adipose tissue. The intervention group had reduced c-peptide, plasminogen-activator-inhibitor-1, and T cell count from baseline to surgery. Myeloid-derived suppressor cells were not statistically different by group. Intervention group anthropometrics improved, including visceral and overall fat loss. No prostate tissue markers changed significantly. Quality of life measures of general and emotional health improved in the intervention group. The intervention group maintained or kept losing to a net loss of 11% initial body weight (95% CI, 8%-14%) at the study end.
CONCLUSIONS: Our study demonstrated improvements in body composition, PCa biomarkers, and quality of life with a weight management intervention.
The present invention relates to a novel multi-specific antibody-cytotoxin conjugate with advanced anti-cancer activity and a composition for preventing or treating cancers. comprising the same. More specifically, the present invention relates to a multi-specific antibody-cytotoxin conjugate comprising: a first antibody binding to a first cancer cell surface antigen; a second antibody binding to a second cancer cell surface antigen; and cytotoxin, wherein the second antibody is linked to the carboxyl terminal of an Fc region of the first antibody and a linker binds to the carboxyl terminal of the second antibody. Further, the present invention relates to a composition for preventing or treating cancers, comprising the conjugate as an active ingredient. The composition of the present invention is used to improve the tumor cell-specific targeting and exhibit enhanced antibody-dependent cytotoxic effect and side effect reducing effect, through strong cytotoxicity, as compared with the therapy using an antibody binding to only one antigen or cytotoxin alone. Further, the conjugate of the present invention can overcome a heterogeneity problem of the existing antibody-cytotoxin conjugate since cytotoxin equally binds to the antibody in a location-specific manner and number-specific manner. Further, the conjugate of the present invention can be utilized for the development of more effective antibody-cytotoxin conjugates due to the binding of heterogeneous antibodies.
Participants in the intervention are African American parents or guardians who have children in the 4th or 5th grade that are 12 or younger. Recruitment was done through schools, housing authorities, community based organizations, and churches. Participants were randomly assigned to participate in one of three interventions delivered by community based interventionists. The enhanced sexuality communication intervention consists of five 2.5 hour sessions conducted over 5 weeks with booster sessions at 12 and 24 months post-intervention. The full sexual communication intervention focuses on general parenting skills and sexual communication skills using a variety of presentation modalities: group discussion, video, and role-plays. The brief sexual communication intervention consists of a single 2.5 hour session in which parents are provided with information on general parenting skills and sexual communication skills. Thus, this intervention seeks to provide the same information as the full sexual communication intervention but in a condensed format with little group participation. The control intervention is a single 2.5 hour session focusing on general child health issues such as diet and exercise rather than parenting and sexual communication.
This study is being done to determine the relationship between tau tangles and cognitive impairment in elderly subjects with different clinical and biomarker profiles of Alzheimer's disease (AD). Subjects will undergo screen that includes neuropsychological testing and brain MRI. This study uses a special type of scan called a PET scan to take pictures of the brain. During the PET scan, a special radioactive dye called 18F-THK-5351 is injected into the body. 18F-THK-5351 sticks to abnormal tangles made of the protein tau. Subjects will have the option to have lumbar puncture performed to measure CSF concentrations of biomarkers.
The intervention dose and duration aims to correct their vitamin D deficiency to sufficient status (total serum 25(OH)D \>/=30 ng/mL or 75 nmol/L). According to an oral cholecalciferol (D3) loading dose guideline for vitamin D-deficient adults (van Groningen et al. 2010), cumulative dose of more than 200,000 IU solubilized vitamin D3 would be applied in current RCT, with make sure the sufficient supplement. Intervention group will receive 144,000 IU in week0 (W0) and then every 2 weeks of 72,000 IU for total 8 weeks (totally 5 times: 144,000 IU wk0/ 72,000 IU wk2/ 72,000 IU wk4/ 72,000 IU wk6/ 72,000 IU wk8), theoretically to achieve sufficient levels of vitamin D.
Techniques for analyzing physician pharmaceutical product recall messages are disclosed. In a preferred embodiment, a method is presented which involves receiving physician recall messages and inputting the messages into a searchable database. A computer program allows a user to define customized message categories. The user definitions include full-text search strings for the messages. The messages are then sorted into the customized message categories based on the definitions. Finally, the sorted messages are presented to the user.
PROBLEM TO BE SOLVED: To obtain an anti-inflammatory medicine composition having promoted absorption of an anti-inflammatory medicine. SOLUTION: This anti-inflammatory medicine composition comprises 0.1-10wt.% of an anti-inflammatory medicine and an unsaturated aliphatic hydrocarbon group-containing nonionic surfactant in the same amount as that of the anti-inflammatory medicine to ten times the amount of the anti-inflammatory medicine. The content of the surfactant is 0.1-10wt.% based on the total of the composition in a system. A nonsteroid anti-inflammatory medicine such as tenoxicam, indomethacin, etc., is used as the anti-inflammatory medicine. A nonsurfactant selected from a polyoxyethylene oleate, a polyglycerol oleate, sorbitan oleate, glyceryl monooleate, a polyoxyethylene oleyl ether and sucrose oleic ester, having 2-15 HLB is preferable as the nonionic surfactant. The anti inflammatory medicine composition can be pharmaceutically manufactured into an oral medicine or an injection.  Percutaneous administration as a skin preparation for external use is most preferable. A dose is 0.1-5g/day/adult in the case of oral administration and 0.1-3g/day/adult in the case of an injection. A dose to be uniformly spread to the affected part is applied once to several times as a skin preparation for external use.
Macrophages are phagocytic cells of the innate immune system. Their accumulation is a hallmark of many inflammatory diseases and they have diverse roles in tissue responses to infection and injury and in tissue repair. As macrophages have a tissue specific and often disease stage specific roles, future therapies directed at macrophage subtypes at certain points in the course of a disease may be more efficacious and result in less systemic side effects, as compared to conventional chemotherapeutics. \[64Cu\] Macrin is designed to detect macrophages by PET imaging. As a result, PET imaging can be used to identify inflammatory "hotspots" and quantitate local macrophage density non-invasively. The investigators studies in mice showed that \[64Cu\] Macrin has excellent pharmacological and pharmacokinetic profile with high target uptake and low retention in background tissues and organs.

The investigators wish to first evaluate in healthy human subjects the pharmacological and pharmacokinetic profile, and the overall safety of the new radiopharmaceutical \[64Cu\] Macrin. The investigators will then establish the concentration of \[64Cu\] Macrin in patients following myocardial infarct, in sarcoidosis and in cancer patients. In a subset of patients where tissue sampling is feasible, we will correlate tracer uptake on imaging to macrophage density on histopathology or with additional standard of care imaging studies.
The invention discloses a group of peptides having a function of easing pain, and a pharmaceutical composition and application of the peptides. The peptides have amino acid sequences as shown in a sequence table SEQ ID No. 1 or a sequence table SEQ ID No. 2, or pharmaceutically acceptable salts of the peptides are provided. Based on the presence of head-end cysteine and terminal cysteine, after one or more amino acids of the amino acid sequence, as shown in the SEQ ID No. 1 or the SEQ ID No. 2, are deleted, substituted or added, polypeptides or pharmaceutically acceptable salts thereof still have the function of easing pain. The polypeptides are formed after one or more amino acids in Loop 3 of GsMTx-4 are deleted, substituted or added, and then the polypeptides having the function of easing pain are screened out from the polypeptides. According to the results of detection for a rat nociceptive pain model by the polypeptides, the inventor proves that a polypeptide short chain series having the function of easing pain is obtained, and the invention is completed.
PURPOSE: A pH sensitive drug-supported calcium carbonate hybrid nanoparticle, a method for preparing the same, and a drug delivery composition containing the same are provided to induce release of a supported drug in a cancer tissue and intracellular endosome and lysosome after targeting. CONSTITUTION: A drug-supported calcium carbonate hybrid nanoparticle contains a drug, calcium carbonate, and a copolymer with a non-ionic hydrophilic polymer part and an ionic polymer part. The calcium carbonate and the ionic polymer part of the copolymer form a core part. The non-ionic hydrophilic polymer part and the polymer part form a shell part. The drug is supported in calcium carbonate of the core part. A method for preparing the hybrid nanoparticle comprises: a step of mixing a copolymer solution containing the non-ionic hydrophilic polymer part and the ionic polymer part with a calcium chloride solution; a step of adding the drug and mixing; and a step of adding a calcium carbonate solution and reacting.
β-Caryophyllene (BCP), a selective agonist for cannabinoid receptor 2 (CB2R), has demonstrated promising protective effects in various pathological conditions. However, the neuroprotective effects of BCP on white matter damage induced by ischemic stroke have not been elucidated previously. In this study, we find that BCP not only improves sensorimotor and cognitive function via CB2R but also mitigates white matter lesions in mice following ischemic stroke. Furthermore, BCP enhances the viability of MO3.13 oligodendrocytes after oxygen-glucose deprivation and reoxygenation (OGD/R), attenuating OGD/R-induced cellular damage and pyroptosis. Notably, these protective effects of BCP are partially enhanced by the NLRP3 inhibitor MCC950 and counteracted by the NLRP3 activator nigericin. In addition, nigericin significantly exacerbates neurological outcomes and increases white matter lesions following BCP treatment in middle cerebral artery occlusion (MCAO) mice. These results suggest that BCP may ameliorate neurological deficits and white matter damage induced by cerebral ischemia through inhibiting NLRP3-mediated pyroptosis.
Patients will receive FOLFOX-6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2) on Day 1, followed by 5-fluorouracil (5-FU) bolus (400 mg/ m2) on Day 1 and 46-hour infusion (2.4 g/ m2) with cycle repeated every 2 weeks over range of 20-24 weeks depending on patients disease state. In addition to Losartan 50 mg/day orally for 4 months.
RATIONALE: The cornea is a unique structure that maintains its clarity by remaining avascular. Corneal injuries can lead to neovascularisation (CNV) and fibrosis and are the third most common cause of blindness worldwide.
OBJECTIVE: Corneal injuries induce an immune cell infiltration to initiate reparative processes. However, inflammation caused by sustained immune cell infiltration is known to be detrimental and can delay the healing process. This study was designed to understand the potential role of neutrophil and epithelial cell crosstalk in post-injury CNV.
METHODS AND RESULTS: Western blotting and immunostaining assays demonstrated that neutrophils infiltrated corneas and underwent pyroptosis following acute alkali injury. In vivo studies showed that genetic ablation of Gasdermin D (GsdmD), a key effector of pyroptosis, enhanced corneal re-epithelialisation and suppressed post-injury CNV. In vitro co-culture experiments revealed that interleukin-1β (IL-1β) was released from pyroptotic neutrophils which suppressed migration of murine corneal epithelial cells. Real-time RT-PCR and immunostaining assays identified two factors, Wnt5a and soluble fms-like tyrosine kinase-1 (sflt-1), highly expressed in newly healed epithelial cells. sflt-1 is known to promote corneal avascularity. Bone marrow transplantation, antibody mediated neutrophil depletion, and pharmacological inhibition of pyroptosis promoted corneal wound healing and inhibited CNV in an in vivo murine corneal injury model.
CONCLUSION: Taken together, our study reveals the importance of neutrophil/epithelium crosstalk and neutrophil pyroptosis in response to corneal injuries. Inhibition of neutrophil pyroptosis may serve as a potential treatment to promote corneal healing without CNV.
KEY POINTS: Neutrophil pyroptosis delays re-epithelialization after corneal injury Compromised re-epithelialization promotes corneal neovascularization after injury Inhibition of post-injury pyroptosis could be an effective therapy to promote corneal wound healing.
The probiotic supplement compound will consist of capsules containing approximately 10\^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.